Alliance Global Partners has initiated coverage on Merus NV (MRUS) with a Buy rating, marking the firm's first assessment of the biotechnology company. Merus NV, based in Utrecht, specializes in the discovery and development of bispecific antibody therapeutics, focusing on immuno-oncology treatments. The company, which went public on May 19, 2016, has a market capitalization of $7.3 billion and employs 260 full-time staff.
Merus's product pipeline includes zenocutuzumab (Zeno), a biclonics antibody aimed at treating lung, pancreatic, and other solid tumors. The company is actively engaged in harnessing the immune system to combat cancer through its innovative technology platform.
As of November 1, 2025, the analyst consensus for Merus NV stands at 3 Strong Buy, 6 Buy, and 14 Hold, with a total of 23 ratings. Upcoming earnings are expected on August 3, 2026, with estimates of an EPS of -$1.40 and revenue of $10.8 million. The latest analyst action prior to this was on August 6, 2025, when Needham maintained a Buy rating.
This update provides insight into the growing interest in Merus NV's potential within the biotechnology sector, particularly as the company advances its innovative therapies.